Form 4 for NAMS NewAmsterdam Pharma Co N.V.

Accepted 2026-03-02 00:00:00 ET · period of report 2026-03-02 · accession 0001193125-26-085947 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-03-02	2026-03-02	NAMS	Davidson Michael H.	CEO, Dir	S - Sale+OE	$33.25	-443.7K	174.1K	-72%	-$14.75M
D	2026-03-02	2026-03-02	NAMS	Davidson Michael H.	CEO, Dir	M - OptEx	—	+443.7K	617.9K	+255%	—
D	2026-03-02	2026-03-02	NAMS	Davidson Michael H.	CEO, Dir	M - OptEx	$0.00	-443.7K	239.3K	-65%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2026-03-02	S	D	443,707	$33.25	174,144	D	—	—
2	Common	Ordinary Shares	2026-03-02	M	A	443,707	—	617,851	D	—	—	(F1) The exercise price of the option is EUR 1.16392.
3	Derivative	Option (right to buy)	2026-03-02	M	D	443,707	$0.00	239,267	D	— · — to 2031-07-06	443,707 Ordinary Shares	(F1) The exercise price of the option is EUR 1.16392. (F2) The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.